Germany · Delayed Price · Currency is EUR | Market Cap | 30.88B |
| Revenue (ttm) | 8.54B |
| Net Income (ttm) | 913.66M |
| Shares Out | n/a |
| EPS (ttm) | 1.84 |
| PE Ratio | 33.80 |
| Forward PE | 22.00 |
| Dividend | 0.30 (0.48%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 1,200 |
| Average Volume | 1,282 |
| Open | 64.88 |
| Previous Close | 64.40 |
| Day's Range | 62.10 - 64.88 |
| 52-Week Range | 62.12 - 85.94 |
| Beta | n/a |
| RSI | 33.95 |
| Earnings Date | Nov 11, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (ALC)
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (ALC)
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon Deal
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon Deal
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR
STAAR Surgical holders should vote against sale to Alcon, Glass Lewis says
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today provided the following state...
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today sent the following letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (N...
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon
(RTTNews) - Defender Capital, a long-term shareholder of STAAR Surgical Co. (STAA) holding approximately 1.5% of the Company's outstanding common stock, issued a statement opposing the proposed acquis...
Alcon's Proposed Acquisition of STAAR Faces Shareholder Opposition
Alcon's Proposed Acquisition of STAAR Faces Shareholder Opposition
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1...
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC)
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC)
Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Swiss Market Settles On Firm Note As Alcon, UBS Group Rise Sharply
(RTTNews) - The Switzerland market closed on a firm note on Friday, gaining in strength after a modestly positive start. Expectations of more monetary easing by the Federal Reserve, and optimism surro...
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breach...
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: ST...
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or...
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), th...
Stifel Maintains Buy Rating for Alcon (ALC), Lowers Price Target to $85 | ALC Stock News
Stifel Maintains Buy Rating for Alcon (ALC), Lowers Price Target to $85 | ALC Stock News
Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance
Alcon Inc. gets upgraded to a Buy again after my prior hold rating. Upside could come from macro-level clinical demand in the eyecare niche, but also a diverse and growing product portfolio in both th...
STAAR Surgical (STAA) Proposes $28 All-Cash Merger with Alcon
STAAR Surgical (STAA) Proposes $28 All-Cash Merger with Alcon